These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 16127006)

  • 21. Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation.
    Leceta J; Gomariz RP; Martinez C; Carrión M; Arranz A; Juarranz Y
    Neuroimmunomodulation; 2007; 14(3-4):134-8. PubMed ID: 18073504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The influence of cyclosporin A on lymphocyte attenuator expression.
    Zeng C; Zhen Y; Shu SA; Wu T; Yi H; Lian ZX; Zhao Y
    J Autoimmun; 2007 Jun; 28(4):234-44. PubMed ID: 17449225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases.
    Konya C; Paz Z; Apostolidis SA; Tsokos GC
    Cytokine; 2015 Oct; 75(2):207-15. PubMed ID: 26028353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of cyclosporine in the treatment of autoimmune disorders.
    Favre H; Miescher PA; Lemoine R
    Transplant Proc; 1994 Dec; 26(6):3194-6. PubMed ID: 7998112
    [No Abstract]   [Full Text] [Related]  

  • 25. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
    Eisenberg R; Albert D
    Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune function in children born to mothers with autoimmune diseases and exposed in utero to immunosuppressants.
    Biggioggero M; Borghi MO; Gerosa M; Trespidi L; Cimaz R; Meroni PI
    Lupus; 2007; 16(8):651-6. PubMed ID: 17711903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Masking of pan-T-cell markers in patients with autoimmune diseases].
    Grunow R; Volk HD; Schwaab J; Barthelmes H; Lande L; von Baehr R
    Dermatol Monatsschr; 1987; 173(7):390-9. PubMed ID: 3498654
    [No Abstract]   [Full Text] [Related]  

  • 28. Modulation of toll-like receptor function has therapeutic potential in autoimmune disease.
    Clanchy FI; Sacre SM
    Expert Opin Biol Ther; 2010 Dec; 10(12):1703-16. PubMed ID: 21039312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analyses of immunosenescent markers in patients with autoimmune disease.
    Thewissen M; Somers V; Venken K; Linsen L; van Paassen P; Geusens P; Damoiseaux J; Stinissen P
    Clin Immunol; 2007 May; 123(2):209-18. PubMed ID: 17317320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Critical involvement of IL-12 in IFN-gamma induction by calcineurin antagonists in activated human lymphocytes.
    Wittmann M; Killig C; Bruder M; Gutzmer R; Werfel T
    J Leukoc Biol; 2006 Jul; 80(1):75-86. PubMed ID: 16641133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Corticosteroid therapy of various systemic diseases (non-neoplastic, noninfectious)].
    Sternon J; Decaux G; Nève P
    Rev Med Brux; 1991 May; 12(5):179-85. PubMed ID: 2057665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunosuppressive therapy].
    Nelius D; Stieglitz R
    Z Arztl Fortbild (Jena); 1971 Jul; 65(14):742-6. PubMed ID: 5123062
    [No Abstract]   [Full Text] [Related]  

  • 33. [Clinical significance of tubuloreticular structures in circulating lymphocytes of patients with erythematodes].
    Horváth A; Schaff Z; Kramer M; Szepesházi K; Ablonczy E; Bognár A; Király K; Lapis K
    Orv Hetil; 1977 Feb; 118(9):500-3. PubMed ID: 840483
    [No Abstract]   [Full Text] [Related]  

  • 34. Regulatory T cells in patients with systemic lupus erythematosus.
    Alvarado-Sánchez B; Hernández-Castro B; Portales-Pérez D; Baranda L; Layseca-Espinosa E; Abud-Mendoza C; Cubillas-Tejeda AC; González-Amaro R
    J Autoimmun; 2006 Sep; 27(2):110-8. PubMed ID: 16890406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.
    Murphy G; Lisnevskaia L; Isenberg D
    Lancet; 2013 Aug; 382(9894):809-18. PubMed ID: 23972423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclosporine as an immunosuppressive agent for autoimmune disease: theoretical concepts and therapeutic strategies.
    Talal N
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):11-5. PubMed ID: 3289200
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunosuppressive therapy in autoimmune diseases].
    Schwarz-Eywill M
    Z Arztl Fortbild Qualitatssich; 1999 Mar; 93(2):93-100. PubMed ID: 10355057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Theoretical basis of immunosuppression in autoimmune diseases].
    Haustein UF
    Dermatol Monatsschr; 1972 Aug; 158(8):547-71. PubMed ID: 4404036
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells.
    González MA; Gonzalez-Rey E; Rico L; Büscher D; Delgado M
    Arthritis Rheum; 2009 Apr; 60(4):1006-19. PubMed ID: 19333946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoglobulins on the surface of lymphocytes in autoimmune disease. II. Lymphocytotoxins on the surface of lymphocytes.
    Gergely P; Szegedi G; Stenszky E; Fekete B; Szabó G; Petrányi G
    Acta Med Acad Sci Hung; 1974; 31(1-2):115-8. PubMed ID: 4549467
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.